Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TTK | P33981 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204949 | 0.95 | SUV39H2 (0.48) | ALKTSHRGLAMAPTALDH1A1 | |
| SCHEMBL3641803 | 0.88 | SIRT6 (0.63) | MAPTALDH1A1SMN1; SMN2PKM | |
| SCHEMBL309660 | 0.88 | IGF1R (0.47) | ALKTSHRGLAMAPTALDH1A1 | |
| SCHEMBL2156628 | 0.87 | PKM (0.58) | ALKTSHRGLAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2207439 | 0.87 | IGF1R (0.47) | ALKTSHRGLAMAPTALDH1A1 | |
| SCHEMBL15358736 | 0.86 | ALDH1A1 (0.53) | TSHRMAPTALDH1A1HSD17B10MAPK1 | |
| SCHEMBL13178105 | 0.85 | SUV39H2 (0.48) | ALKTSHRMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL519768 | 0.82 | NPC1 (0.49) | ALKALDH1A1SMN1; SMN2TTKGAA | |
| SCHEMBL310231 | 0.81 | KCNH2 (0.45) | ALKMAPTHSD17B10MAPK1GAA | |
| SCHEMBL6151800 | 0.81 | GAA (0.59) | TSHRMAPTALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-113811324-B | Small molecule local Focal Adhesion Kinase (FAK) inhibitors | 达纳-法伯癌症研究公司 | 2024-09-24 | — | — | CN | disclosed |
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3965803-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | ALK 1473/4885TSHR 4386/4885GLA 2380/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | ALK 2832/4885TSHR 2982/4885GLA 3379/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALK 144/4885TSHR 2782/4885GLA 4726/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | ALK 2832/4885TSHR 2982/4885GLA 3379/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | ALK 2832/4885TSHR 2982/4885GLA 3379/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | ALK 285/4885TSHR 74/4885GLA 2943/4885 |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | PTK2, CTTN, TNK2 | ALK 1473/4885TSHR 4386/4885GLA 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.